Background: The Fontan operation creates a total cavopulmonary connection, a circulation in which the importance of pulmonary vascular resistance is magnified. Over time, this circulation leads to deterioration of cardiovascular efficiency associated with a decline in exercise performance. Rigorous clinical trials aimed at improving physiology and guiding pharmacotherapy are lacking.
Methods: The FUEL trial (Fontan Udenafil Exercise Longitudinal) was a phase III clinical trial conducted at 30 centers. Participants were randomly assigned udenafil, 87.5 mg twice daily, or placebo in a 1:1 ratio. The primary outcome was the between-group difference in change in oxygen consumption at peak exercise. Secondary outcomes included between-group differences in changes in submaximal exercise at the ventilatory anaerobic threshold, the myocardial performance index, the natural log of the reactive hyperemia index, and serum brain-type natriuretic peptide.
Results: Between 2017 and 2019, 30 clinical sites in North America and the Republic of Korea randomly assigned 400 participants with Fontan physiology. The mean age at randomization was 15.5±2 years; 60% of participants were male, and 81% were white. All 400 participants were included in the primary analysis with imputation of the 26-week end point for 21 participants with missing data (11 randomly assigned to udenafil and 10 to placebo). Among randomly assigned participants, peak oxygen consumption increased by 44±245 mL/min (2.8%) in the udenafil group and declined by 3.7±228 mL/min (-0.2%) in the placebo group (P=0.071). Analysis at ventilatory anaerobic threshold demonstrated improvements in the udenafil group versus the placebo group in oxygen consumption (+33±185 [3.2%] versus -9±193 [-0.9%] mL/min, P=0.012), ventilatory equivalents of carbon dioxide (-0.8 versus -0.06, P=0.014), and work rate (+3.8 versus +0.34 W, P=0.021). There was no difference in change of myocardial performance index, the natural log of the reactive hyperemia index, or serum brain-type natriuretic peptide level.
Conclusions: In the FUEL trial, treatment with udenafil (87.5 mg twice daily) was not associated with an improvement in oxygen consumption at peak exercise but was associated with improvements in multiple measures of exercise performance at the ventilatory anaerobic threshold.
Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02741115.
Keywords: Fontan procedure; exercise test; heart defects, congenital; phosphodiesterase 5 inhibitor.
Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.Circulation. 2011 Mar 22;123(11):1185-93. doi: 10.1161/CIRCULATIONAHA.110.981746. Epub 2011 Mar 7. Circulation. 2011. PMID: 21382896 Free PMC article. Clinical Trial.
Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial.Am Heart J. 2018 Jul;201:1-8. doi: 10.1016/j.ahj.2018.03.015. Epub 2018 Apr 3. Am Heart J. 2018. PMID: 29910047 Free PMC article. Review.
PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.Am Heart J. 2015 Jun;169(6):813-822.e3. doi: 10.1016/j.ahj.2015.03.018. Epub 2015 Apr 1. Am Heart J. 2015. PMID: 26027619 Clinical Trial.
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024. JAMA. 2013. PMID: 23478662 Free PMC article. Clinical Trial.
Exercise limitation in patients with Fontan circulation: a review.J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):775-81. doi: 10.2459/JCM.0b013e328011c999. J Cardiovasc Med (Hagerstown). 2007. PMID: 17885514 Review.
- UG1 HL135665/HL/NHLBI NIH HHS/United States
- UG1 HL135666/HL/NHLBI NIH HHS/United States
- U10 HL109818/HL/NHLBI NIH HHS/United States
- UG1 HL135680/HL/NHLBI NIH HHS/United States
- UG1 HL135646/HL/NHLBI NIH HHS/United States
- UG1 HL135683/HL/NHLBI NIH HHS/United States
- UG1 HL135685/HL/NHLBI NIH HHS/United States
- UG1 HL135689/HL/NHLBI NIH HHS/United States
- U10 HL068270/HL/NHLBI NIH HHS/United States
- KL2 TR002367/TR/NCATS NIH HHS/United States
- UG1 HL135678/HL/NHLBI NIH HHS/United States
- U24 HL135691/HL/NHLBI NIH HHS/United States
- UG1 HL135682/HL/NHLBI NIH HHS/United States